Authors


Agnes Y. Y. Lee, MD

Latest:

Management of Venous Thromboembolism in Cancer Patients

Venous thromboembolism is a common complication in patients with cancer. The management of deep-vein thrombosis and pulmonary embolism can be a considerable challenge in these patients. Diagnosing venous


Ahmad A. Tarhini, MD, PhD

Latest:

Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced Melanoma

Panelists discuss how the ITC analysis of first-line dual-IO treatments in advanced melanoma highlights the potential for nivolumab plus relatlimab to offer similar efficacy to nivolumab plus ipilimumab, with a more favorable safety profile, particularly in terms of lower rates of severe immune-related adverse events.


Ahmad Halwani, MD

Latest:

Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation

Although ibrutinib-related atrial fibrillation (IRAF) occurs in up to 11% of patients in clinical trials, these studies have rarely fully characterized bleeding events or risk factors for bleeding when ibrutinib is combined with anticoagulation. Furthermore, guidelines do not provide direction regarding the preferred anti-arrhythmic agent for IRAF.


Ahmad R. Safa, MD, PhD

Latest:

Irinotecan and Gemcitabine in Patients With Solid Tumors: Phase I Trial

Using a day 1 and 8, every-3-week schedule, our purpose was to determine the maximum tolerated dose of irinotecan (CPT-11, Camptosar) that can be administered immediately after gemcitabine (Gemzar) at a dose of 1,000 mg/m² IV. In this phase I trial, the maximum tolerated dose was defined as the dose level immediately below the level in which two of the first three patients in any cohort, or at least two of six patients in any expanded cohort, experienced dose-limiting toxicity. Dose-limiting toxicity pertained only to toxicity during the first cycle of treatment. Escalation of irinotecan was planned in groups of three patients, with three additional patients added at the first indication of dose-limiting toxicity. A total of 19 patients have been enrolled.


Aimee L. Quan, MD

Latest:

Brain Metastases in Small Cell Lung Cancer

The purpose of this paper is to provide an overview of the clinical presentation, diagnosis, and treatment of brain metastases in patients with SCLC, with a focus on current trends and developments in the treatment of this disease.


Aimee Wilkin, MD

Latest:

Prophylaxis Against Fungal Infections and Cytomegalovirus Disease After Bone Marrow Transplantation

Among the serious complications associated with bone marrow transplantation are invasive fungal infections caused by organisms such as Candida and Aspergillus species and end-organ disease caused by


Aimee Wonderlick, MS

Latest:

At the Crossroads: The Intersection of the Internet and Clinical Oncology

The Internet is rapidly becoming a third party in the doctor-patient relationship. The World Wide Web, electronic mail (e-mail), and discussion groups have dramatically increased the quantity of medical and health


Aimery De Gramont, MD

Latest:

Pemetrexed in Advanced Colorectal Cancer

Pemetrexed (Alimta) shows single-agent activity in advancedcolorectal cancer. In two phase II studies in which patients receivedpemetrexed at 600 mg/m2 or 500 mg/m2 as first-line treatment for metastaticdisease, objective response rates were 15.4% and 17.2%.


Ajay K. Nooka, MD

Latest:

Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.


Ajay Niranjan, MD, MBA

Latest:

Gamma Knife Radiosurgery for 5 to 10 Brain Metastases: A Good Option for Upfront Treatment

The aggressive management of brain metastases with SRS has supplanted radiation therapy in an effort to maintain patient quality of life in an era of advancing systemic cancer options.


Ajithkumar Puthillath, MD

Latest:

Neoadjuvant Chemoradiation for Rectal Cancer: Is More Better?

Neoadjuvant chemoradiation has become the favored adjuvant treatment for stages II and III rectal cancer. Compared to postoperative chemoradiation, this modality of treatment has been shown to be superior in terms of toxicity, local relapse, and sphincter-saving.[1] This article will focus on the evolution of neoadjuvant chemotherapy over the past 2 decades, current acceptable neoadjuvant standards, and current investigational regimens.


Ajmel A. Puthawala, MD

Latest:

ACR Appropriateness Criteria® Management of Vaginal Cancer

This article represents the consensus opinion of an expert panel and may be used to inform clinical recommendations in vaginal cancer management.


Aju Mathew, MD, MPhil

Latest:

Optimal Use of Bone-Targeted Agents in Breast Cancer

It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.


Aki Morikawa MD, PhD

Latest:

Osteoclast Inhibitors: A Multifaceted Tool in the Management of Breast Cancer

There are still questions to be answered about the use of osteoclast inhibitors in the care of patients with breast cancer. The optimal duration and dosing schedule and how to improve treatment compliance are important issues to address.


Aki Ohinata, MS, PA-C

Latest:

Clinical Management of EGFRI Dermatologic Toxicities: The Nursing Perspective

All nursing personnel actively participate in the nursing process, with the registered nurse taking primary responsibility. Five steps in the nursing process include assessment, diagnosis, planning, implementation, and evaluation. Health-care professionals have more than 10 years of experience with EGFR inhibitors in the oncology setting. To date, the application of the nursing process to assist in patient management has not been previously published or thoroughly described in the literature. This article will apply the nursing process utilizing current recommendations regarding the assessment and management of dermatologic toxicities associated with EGFR inhibitors.


Akihiko Takeda, MD

Latest:

Synopsis of Angiogenesis Inhibitors in Oncology

Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease the activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survival factor activity.


Akila N. Viswanathan, MD, MPH

Latest:

Ovarian Cancer

Despite the fact that it is highly curable if diagnosed early, ovarian cancer causes more mortality in American women each year than all other gynecologic malignancies combined.


Akiva Mintz, MD, PhD, MHA

Latest:

PET/CT in Prostate Cancer: An Unmet Clinical Need

Molecular imaging in prostate cancer can play the additional critical role of an early biomarker for response to therapy, similar to how 18F-FDG is used in other malignancies.


Aknar Calabrich, MD

Latest:

Trastuzumab: Mechanisms of Resistance and Therapeutic Opportunities

The human epidermal growth factor receptor 2 (HER2) is a transmembrane receptor with tyrosine kinase activity overexpressed in about 20% to 25% of invasive carcinomas of the breast.


Aknar F. C. Calabrich, MD

Latest:

Adjuvant Chemotherapy for Stage II Colon Cancer

Adjuvant therapy is defined as any treatment administered after surgical resection of a primary tumor with the intent of improving the patient’s outcome by eliminating any occult, viable tumor cells that may have remained after surgery.


Al B. Benson III, MD, FACP

Latest:

Pancreatic, Neuroendocrine GI, and Adrenal Cancers

This management guide covers the risk factors, symptoms, diagnosis, staging, and treatment of pancreatic cancer, pancreatic cystic neoplasms, pancreatic endocrine tumors (PETs), carcinoid tumors of the GI tract, adrenocortical carcinoma, and pheochromocytoma.


Al Barqawi, MD

Latest:

Prostate Cancer in a Man With Multiple Previous Cancers

patient is a 67-year-old male with mild obstructive symptoms and an American Urology Association symptom score of 8.[1] He was noted to have a prostate-specific antigen (PSA) level of 3.2 ng/mL. Because this represented a significant increase in his PSA velocity (rate of change over time), he proceeded to have a biopsy, which was positive for prostate cancer. He has no other complaints and visits us for an opinion on the treatment of his prostate cancer.


Al V. Taira, MD

Latest:

ACR Appropriateness Criteria® Postradical Prostatectomy Irradiation in Prostate Cancer

The purpose of this article is to present an updated set of American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of radiation therapy in postprostatectomy prostate cancer.


Alaa Muslimani, MD

Latest:

How We Treat Tumor Lysis Syndrome

When tumor cells are rapidly broken down and their contents released into the extracellular space, the released ions and compounds can cause metabolic disturbances too great to be neutralized by the body's normal mechanisms.


Alain Ravaud, MD, PhD

Latest:

UFT and Oral Calcium Folinate as First-Line Chemotherapy for Metastatic Gastric Cancer

Locally advanced or metastatic adenocarcinoma of the stomach still carries a poor prognosis, with 5-year survival rates of < 15%. Palliative chemotherapeutic regimens for this disease are largely 5-FU–based. We


Alain Zeimet, MD, PhD

Latest:

Is Neoadjuvant Chemotherapy in Ovarian Cancer an Excuse for Insufficient Surgery?

Surgical debulking of epithelial ovarian carcinoma has been a mainstay of therapy for more than 50 years-since the approach was first advocated by Meigs in 1934.[1] In 1968, Munnell[2] introduced the idea of the "maximum surgical effort”-essentially the removal of as much cancer as possible.


Alaina Vrontikis

Latest:

Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation

Although ibrutinib-related atrial fibrillation (IRAF) occurs in up to 11% of patients in clinical trials, these studies have rarely fully characterized bleeding events or risk factors for bleeding when ibrutinib is combined with anticoagulation. Furthermore, guidelines do not provide direction regarding the preferred anti-arrhythmic agent for IRAF.


Alan B. Astrow, MD

Latest:

The Timing of Breast Cancer Surgery During the Menstrual Cycle

Contemporary breast cancer treatment research has focused on systemic postoperative adjuvant treatment and the elimination of established micrometastases. An alternative approach addresses the potential for seeding at the time of primary surgery. Several retrospective reports have suggested that the hormonal milieu during lumpectomy or mastectomy impacts on the likelihood of tumor cell shedding and implantation at distant sites.


Alan B. Colowick, MD, MPH

Latest:

Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia

The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by


Alan B. Sandler, MD

Latest:

Advanced Non-Small-Cell Lung Cancer

It's been an interesting time for those of us who treat patients with lung cancer. Over the past few years, non-small-cell lung cancer (NSCLC) has been a target for the numerous companies developing agents that inhibit receptors, growth factors, signaling molecules, and genes involved in tumor growth and development. The "biologic-targeted" approach to treatment is still in its infancy, but it has already given us great expectations, some surprises, some disappointments, and, ultimately, satisfaction that we now have a nonchemotherapeutic option.